182 related articles for article (PubMed ID: 27650797)
1. A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.
Du F; Yuan P; Zhao ZT; Yang Z; Wang T; Zhao JD; Luo Y; Ma F; Wang JY; Fan Y; Cai RG; Zhang P; Li Q; Song YM; Xu BH
Sci Rep; 2016 Sep; 6():33825. PubMed ID: 27650797
[TBL] [Abstract][Full Text] [Related]
2. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
7. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
[TBL] [Abstract][Full Text] [Related]
8. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
Di Cosimo S; Appierto V; Pizzamiglio S; Tiberio P; Iorio MV; Hilbers F; de Azambuja E; de la Peña L; Izquierdo M; Huober J; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Daidone MG
Clin Cancer Res; 2019 Jul; 25(13):3887-3895. PubMed ID: 30814109
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
[TBL] [Abstract][Full Text] [Related]
10. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E
Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399
[TBL] [Abstract][Full Text] [Related]
11. Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.
Sonnenblick A; Brohée S; Fumagalli D; Rothé F; Vincent D; Ignatiadis M; Desmedt C; Salgado R; Sirtaine N; Loi S; Neven P; Loibl S; Denkert C; Joensuu H; Piccart M; Sotiriou C
Oncotarget; 2015 Oct; 6(30):30306-16. PubMed ID: 26358523
[TBL] [Abstract][Full Text] [Related]
12. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
Pizzamiglio S; Cosentino G; Ciniselli CM; De Cecco L; Cataldo A; Plantamura I; Triulzi T; El-Abed S; Wang Y; Bajji M; Nuciforo P; Huober J; Ellard SL; Rimm DL; Gombos A; Daidone MG; Verderio P; Tagliabue E; Di Cosimo S; Iorio MV
Cancer Med; 2022 Jan; 11(2):332-339. PubMed ID: 34921525
[TBL] [Abstract][Full Text] [Related]
13. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
[TBL] [Abstract][Full Text] [Related]
15. Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2
Decker JT; Hall MS; Blaisdell RB; Schwark K; Jeruss JS; Shea LD
Biotechnol Bioeng; 2018 Oct; 115(10):2613-2623. PubMed ID: 29981261
[TBL] [Abstract][Full Text] [Related]
16. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
17. A four-miRNA signature as a novel biomarker for predicting survival in endometrial cancer.
Wu YS; Lin H; Chen D; Yi Z; Zeng B; Jiang Y; Ren G
Gene; 2019 May; 697():86-93. PubMed ID: 30779946
[TBL] [Abstract][Full Text] [Related]
18. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
19. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
20. A microRNA expression signature predicts meningioma recurrence.
Zhi F; Zhou G; Wang S; Shi Y; Peng Y; Shao N; Guan W; Qu H; Zhang Y; Wang Q; Yang C; Wang R; Wu S; Xia X; Yang Y
Int J Cancer; 2013 Jan; 132(1):128-36. PubMed ID: 22674195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
